Biomea Fusion, Inc. - Common Stock – Cashflow (NASDAQ:BMEA)

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -35.44 M-62.42 M-96.59 M-119.89 M-70.37 M -56.37 M Mittelzufluss aus Investitionstätigkeit -33.35 M27.34 M-2.22 M-362 K-362 K — Zahlungsströme aus der Finanzierungstätigkeit 153.19 M1.24 M163.8 M1.67 M67.9 M — Freier Cashflow -35.44 M-62.42 M-96.59 M-119.89 M-70.37 M -56.37 M

Nachrichten

Biomea Fusion: Citizens sieht über 500 % Kurspotenzial dank Diabetes-Wirkstoff

Biomea: Positive Phase-2-Daten für Diabetes-Wirkstoff Icovamenib

Biomea Fusion, Inc. (BMEA) Discusses Menin Inhibition Mechanism and Therapeutic Potential in Diabetes Transcript

Biomea Fusion, Inc. (BMEA) Discusses Phase I Data and Clinical Potential of Oral GLP-1 Receptor Antagonist for Obesity Transcript

Biomea Fusion, Inc. (BMEA) Presents at 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - Slideshow (NASDAQ:BMEA) 2026-03-16

Biomea Fusion, Inc. (BMEA) Presents at The Citizens Life Sciences Conference 2026 - Slideshow (NASDAQ:BMEA) 2026-03-12

Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow (NASDAQ:BMEA) 2026-01-16

Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Rodman & Renshaw initiates Biomea Fusion stock with Buy rating

Biomea Fusion legt strategische Prioritäten für Diabetes- und Adipositas-Medikamente bis 2026 fest

Biomea Fusion outlines 2026 diabetes and obesity drug development plans

Positive Studiendaten zu Diabetes-Mittel beflügeln Aktie von Biomea Fusion